A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Summary

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with relapsed/refractory hematologic malignancies. The purpose of this study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be used in subsequent development of PRT1419.

Timeline

Start

2020-09-28

Primary completion

2022-03-21

Completion

2022-03-21

Drugs

Indications